KU Leuven Stem Cell Platform KU Leuven
Insufficient drug safety and lack of efficacy are the main reasons for the high failure rate of molecules in clinical development. The use of patient−derived, human cell systems in preclinical research holds the promise of leading to more efficacious and safer drugs, thus reducing ‘attrition’ and its associated costs in drug development. KU Leuven Stem Cell Platform (KUL−STEM) will develop state and beyond state of the art technologies that ...